HC Wainwright Has Strong Forecast for PRLD FY2026 Earnings

Prelude Therapeutics Incorporated (NASDAQ:PRLD – Free Report) – Investment analysts at HC Wainwright boosted their FY2026 EPS estimates for shares of Prelude Therapeutics in a research note issued to investors on Wednesday, November 18th. HC Wainwright analyst R. Burns now expects that the company will earn ($0.53) per share for the year, up from their previous estimate of ($0.54). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Prelude Therapeutics’ current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for Prelude Therapeutics’ Q1 2027 earnings at ($0.15) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.17) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.63) EPS.

Prelude Therapeutics (NASDAQ:PRLD – Get Free Report) last posted its quarterly earnings results on Monday, November 16th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.13). The business had revenue of $5.65 million for the quarter, compared to analyst estimates of $29.00 million.

A number of other equities research analysts have also recently commented on the company. Citigroup reissued a “market outperform” rating on shares of Prelude Therapeutics in a report on Wednesday, October 14th. Wall Street Zen lowered Prelude Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, September 19th. JPMorgan Chase & Co. started coverage on Prelude Therapeutics in a research report on Thursday, September 17th. They set an “overweight” rating and a $12.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Prelude Therapeutics in a research report on Tuesday, October 27th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $8.75.

Get Our Latest Stock Report on PRLD

Prelude Therapeutics Stock Performance

Shares of Prelude Therapeutics stock opened at $3.23 on Friday. The company has a market capitalization of $258.63 million, a P/E ratio of -5.47 and a beta of 1.22. The company has a fifty day moving average of $3.83 and a 200 day moving average of $4.10. Prelude Therapeutics has a fifty-two week low of $1.29 and a fifty-two week high of $6.83.

Institutional Investors Weigh In On Prelude Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Spark Investment Management LLC purchased a new stake in Prelude Therapeutics during the second quarter valued at $56,000. GSA Capital Partners LLP bought a new position in Prelude Therapeutics during the second quarter valued at $68,000. Hsbc Holdings PLC bought a new position in Prelude Therapeutics during the second quarter valued at $74,000. Polymer Capital Management US LLC purchased a new position in shares of Prelude Therapeutics in the 3rd quarter worth $55,000. Finally, American Century Companies Inc. purchased a new position in shares of Prelude Therapeutics in the 3rd quarter worth $86,000. 79.72% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Prelude Therapeutics

These are some of the PRLD headlines that stood out recently:

  • Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $8 price target. The firm also modestly improved its loss estimates: FY2026 EPS to ($0.53) from ($0.54), and FY2027 EPS to ($0.63) from ($0.67). The higher target is well above the recent share price, though analyst targets are not guarantees. HC Wainwright Reaffirms Buy Rating for Prelude Therapeutics
  • Positive Sentiment: A report said Prelude narrowed its third-quarter net loss to $12.5 million, a potentially encouraging sign of improved cost control. Prelude Therapeutics stock narrows Q3 net loss to USD 12.5 million
  • Negative Sentiment: Despite the estimate improvements, HC Wainwright still forecasts losses in each quarter of 2027, with full-year EPS of ($0.63). Ongoing losses remain a risk for investors.

About Prelude Therapeutics

(Get Free Report)

Prelude Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer. The company researches small-molecule therapies designed to target biological mechanisms that contribute to tumor growth and survival. Its research has focused on targets including cancer-related proteins involved in gene regulation and cell signaling. Prelude’s pipeline has included investigational drug candidates for patients with cancers that may be driven by particular molecular changes; these candidates are experimental and have not been established as approved treatments.

See Also

Earnings History and Estimates for Prelude Therapeutics (NASDAQ:PRLD)

Receive News & Ratings for Prelude Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prelude Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.